Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Semaglutide in type 2 diabetes with chronic kidney disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, semaglutide also significantly reduced the rate of eGFR decline (annual slope difference 1•16 mL/min per 1•73 m², 0•86-1•47), MACE (HR 0•82, 0•68-0•98), and all-cause mortality (HR 0•80, 0•67-0•95)”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Treatment with injectable semaglutide 1 mg once weekly reduced the relative risk for the composite primary outcome (ie, ≥50% eGFR decline, eGFR <15 mL/min per 1•73 m², dialysis or transplant, or death due to kidney disease or cardiovascular disease) by 24% compared with placebo (HR 0•76, 0•66-0•88).26”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Moreover, the GLP-1 receptor agonist, semaglutide reduced the risk of a composite kidney end point in a dedicated kidney outcome trial.11”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [11]
In the citing paper
“semaglutide can reduce the progression of chronic kidney disease in patients with and without diabetes and even in those taking SGLT2 inhibitors [12–14].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [13]
In the citing paper
“Once-weekly treatment with 1 mg semaglutide reduced the risk of the primary composite outcome by 24% and delayed the progression of kidney dysfunction over a period of 4 years (75).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [75]
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 1,101–1,200 of 1,871
Ko, H. Y., Hong, B., Bea, S., Bae, J. H., Cho, Y. M., Chang, Y., Ryu, S., Byrne, C. D., & Shin, J. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112921 · Cited by 2
Mahmod, M., Dennis, A., Lian, J., Langford, C., Rahimi, K., & Wamil, M. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10629-z · Cited by 2
German, J., Cordioli, M., Tozzo, V., Urbut, S., Arumäe, K., Smit, R. A. J., Lee, J., Li, J. H., Janucik, A., Ding, Y., et al. (2024) · medRxiv · doi:10.1101/2024.09.11.24313458 · Cited by 1
Ozojide, K. O., Ozigbo, A. A., Ghartey, K. K., Okobi, O. E., Muoghalu, N., Gbagba, O. A., Lawal, A. D., (Fakoya), T. A., Egyin, S., Anyanwu, F. C., et al. (2025) · Cureus · doi:10.7759/cureus.87124 · Cited by 2
“Moreover, chronic conditions like type 2 diabetes are now accepted to have some form of relationship with the dysregulation of gastrointestinal processes and could interact with the symptoms of IBS in multifaceted ways [13,14].”
Ahmad, M., Sikandar, A., Aziz, A., Sumodi, W. B. A., Hans, A., & Usman, M. (2025) · Cureus · doi:10.7759/cureus.89514 · Cited by 2
“Building upon early trials like LEADER, SUSTAIN-6, and REWIND, several recent high-powered trials, such as SOUL [4] (N=9,650), FLOW [5] (N=3,533), and the STEP-HFpEF program [6] (N=1,145), have refined our understanding of semaglutide’s impact on both CV and cardiorenal outcomes.”
InfluentialAnderson, B. J., Daele, D. J. V., Claussen, A. D., Tanenbaum, Z. G., & Owen, S. R. (2026) · Annals of Otology Rhinology & Laryngology · doi:10.1177/00034894261450724 · Cited by 1
Mechanisms of glucagon-like-peptide 1 in the brain beyond metabolic effects
Kim, K. S., Park, J. S., & Choi, H. J. (2025) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2448320.160 · Cited by 3
“Furthermore, GLP-1 drugs have also been shown to affect inflammation in the heart, kidney, and liver [98,99].”
Moriya, S., Iwata, H., Chikata, Y., Funamizu, T., Doi, S., Koike, T., Abe, K., Matsuo, R., Wada, H., Naito, R., et al. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00243-7 · Cited by 1
“More-over, sodium-glucose cotransporter-2 (SGLT2) inhibitors [9, 10, 29], mineral corticoid receptor antagonists (MRAs) [8, 30, 31] and GLP-1 receptor agonists [32, 33] have emerged to be promise in reducing proteinuria in patients with CKD.”
Abdelnabi, M. H., Chaisrimaneepan, N., Castillo‐Rodriguez, C., Eshak, N., Sullivan, M. M., Ibrahim, R., Pham, H. N., Farina, J., Ayoub, C., Nagaraja, V., et al. (2025) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-025-01124-z · Cited by 1
“GLP-1 analogue efficacy in reducing proteinuria in diabetic kid - neys has also been reported [72, 73] though studies in Lupus nephritis with proteinuria have yet to be reported investigating the potential role of GLP-1 analogues as nephropro-tective agents.”
D’Alessio, D. A., & Kahn, S. E. (2024) · Diabetes · doi:10.2337/dbi24-0046 · Cited by 1
Dayel, F. F. B., Alanazi, R. J., Alenazi, M. A., Alkhalifah, S., Dayel, D. F. B., Mawkili, W., & Alwhaibi, A. M. (2026) · Healthcare · doi:10.3390/healthcare14070845 · Cited by 1
“In the FLOW study, semaglutide significantly reduced major kidney events and cardiovascular death vs. a placebo in patients with type 2 diabetes mellitus and established chronic kidney disease [43].”
GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Game Charger in the Field?
Doumani, G., Theofilis, P., Tsimihodimos, V., & Kalaitzidis, R. (2024) · Life · doi:10.3390/life14111478 · Cited by 5
Does Our Classification System for CKD Serve the US Population Well?
Kattah, A. G., & Rule, A. D. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000433 · Cited by 1
Pérez, P. C., Rodríguez, A., Broseta, J. J., Solé‐González, E., Castel, M., Rodríguez, J., Cuadrado‐Payán, E., Rodríguez‐Espinosa, D., Sandoval, E., Cases, A., et al. (2025) · Clinical Transplantation · doi:10.1111/ctr.70347 · Cited by 2
“Currently, specific treatments are available that have been shown to delay CKD progression and improve cardiovascular (CV) and non-CV clinical events, including ACEi/ARBs[21],SGLT2inhibitors[22],finerenone[23],andGLP-1 analogs [23].”
Advances and Challenges in Holistic Treatment of Cardiometabolic Kidney Disease as One Entity
Bozkurt, B. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.10.002 · Cited by 2
The biology of PKM2 in the metabolism and senescence in diabetic kidney disease
Kayes, M. I., & Kanasaki, K. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70231 · Cited by 1
“Large outcome trials, such as LEADER, SUSTAIN-6, AWARD-7, and FLOW, have demonstrated that GLP-1RAs like liraglutide, semaglutide, and dulaglutide slow the decline of kidney function and reduce the risk of new-onset macroalbuminuria 62 – 64 .”
Effects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review
van Maren, S., van Doorn, E. P. M., Smits, M. M., Tack, C. J., van Rossum, E. F. C., & Messaoudi, S. E. (2026) · Netherlands Heart Journal · doi:10.1007/s12471-026-02073-3 · Cited by 1
Wang, M., Li, W., Cheng, Q., et al. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.71251 · Cited by 1
“…(DKD), a metabolic complication of type 2 diabetes, has emerged as the leading cause of end-stage renal disease (ESRD) worldwide, driven by progressive renal fibrosis and irreversible functional decline (Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group 2024; Perkovic et al. 2024).”
Liu, Y.-C., Xiao, J., & Chen, L. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i2.115021 · Cited by 1
Extending Kidney Protective Therapy to Type 1 Diabetes
Neumiller, J. J., & Tuttle, K. R. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000685 · Cited by 1
Self-citationHandelsman, Y., Cheng, A. Y. Y., Fadini, G. P., Kushner, P. R., Bonnet, F., Fioretto, P., Kadowaki, T., Kanumilli, N., Cos, X., Frese, T., et al. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03559-7 · Cited by 1
“This is consistent with the wider literature where SGLT2is have shown significant positive outcomes regardless of T2D or obesity status [11, 12, 14].”
InfluentialSelf-citationNovel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus
Kugathasan, L., Katz, A., Muskiet, M. H. A., Sridhar, V. S., Scott, J., Yi, T. W., & Cherney, D. Z. I. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106547 · Cited by 2
Glp-1 receptor agonists: A boon for kidney transplant recipients?
Pullen, L. C. (2025) · American Journal of Transplantation · doi:10.1016/j.ajt.2025.05.032 · Cited by 1
Alkhezi, O. S., Alfehaid, L., Alanezi, A., Alotaibi, M., & Alshaya, O. A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1805015 · Cited by 2
Obesity management medications for the surgeon
Harris, M., Mahdi, S., Fairfield, C. J., Brown, L. R., Wadley, M., & Miras, A. D. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103307 · Cited by 1
Extending the Window to Preemptive Kidney Transplant Through Sleeve Gastrectomy
Montgomery, J. R., Estrada, M. M., & Orandi, B. J. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.04.019 · Cited by 1
The Latest topics of Standards of Care in Diabetes 2025: Focusing on GLP-1RA
Bando, H., Wood, M., & Ebe, K. (2024) · Asploro Journal of Biomedical and Clinical Case Reports · doi:10.36502/2024/asjbccr.6386 · Cited by 1
Concomitant use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure
Khademi, R., & Shoar, S. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00319-y · Cited by 1
“…be considered when additional treatment goals include weight reduction, improved glycemic control, chronic kidney disease risk reduction, or lowering atherosclerotic cardiovascular risk, particularly in patients with obesity or established Atherosclerotic Cardiovascular Disease (ASCVD) [7, 16, 47].”
Pattern of semaglutide prescription in a real-world Canadian patient cohort
Farahvash, A., Lee, M. C. M., Jain, R., & Jaakkimainen, L. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.06.006 · Cited by 5
Shafi, T., & Bobart, S. A. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.04.052 · Cited by 1
Es, M. V., Erzeel, J., Wever, M. D., Dupont, M., Nijst, P., Penders, J., Tang, W. H. W., Savarese, G., Sprangers, B., Martens, P., et al. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag054 · Cited by 1
Semaglutide Hype or Hope: Evidence-based Review in Diabesity
Gupta, S., Makkar, B. M., Kesavadev, J., & Kumar, A. M. V. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1439 · Cited by 1
Kazory, A., & Ronco, C. (2026) · Kidney360 · doi:10.34067/kid.0000001140 · Cited by 2
Tratamiento farmacológico de la diabetes mellitus tipo 2
Soidán, F. J. G., & Villanueva, J. R. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103143 · Cited by 6
Pedicino, D., & Volpe, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf277 · Cited by 1
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062757 · Cited by 3
Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications
Odeleye, V., Singh, N., Gautam, S., Shannon, E., Bibb, W. M., McClure, M., & Paul, T. K. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02357-5 · Cited by 1
“These findings established semaglutide as the first GLP-1 receptor agonist to demonstrate kidney disease–modifying efficacy in a dedicated renal outcomes trial [ 25].”
Khokhar, M., Yadav, D., & Sharma, P. (2026) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-026-01417-5 · Cited by 1
“GLP-1R expression in renal proximal tubular cells mediates natriuresis, reduced glomerular hyperfiltration, and attenuated albuminuria—effects confirmed in both the FLOW [ 8] and SELECT [1] trials.”
Incretin Mimetics in Cancer and Cardiovascular Disease
Leong, D. P., Gong, S., Sattar, N. A., Narayan, V., Reizine, N. M., Gerstein, H. C., & Vellky, J. E. (2026) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.12.003 · Cited by 3
Cardiometabolic and Diabetes Management in Older Adults
Marion, W., & Neeland, I. J. (2026) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2025.12.005 · Cited by 1
Bashier, A. M., Rukhaimi, M. A., Alhadari, A. K., Hussein, D., Hassanein, M. M., Abdelgadir, E., Rashid, F., Alhelfi, M., Kumar, D. N., Alalawi, F. J. A., et al. (2026) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0045-1814429 · Cited by 1
Chronic kidney disease progression after cardiac surgery: a retrospective multicentre study
Bille, S., Lindhardt, R. B., Riber, L. P., Juhl‐Olsen, P., Ravn, H. B., & Rasmussen, S. B. (2025) · BJA Open · doi:10.1016/j.bjao.2025.100506 · Cited by 2
Cheng, Y.-S., Chung, C.-H., Kuo, S.-M., Lin, C.-P., Weng, T.-H., Su, S.-C., Lu, C.-H., Kuo, F.-C., Chien, W.-C., Liang, Y.-J., et al. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251400536 · Cited by 3
Merker, L., Ebert, T., Schleicher, E. D., Isermann, B. H., & Guthoff, M. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-8500 · Cited by 2
Sato, G. E., Uchino, H., Takuma, K., Saito, M., Fuchigami, A., Iwata, Y., Yoshikawa, F., & Hirose, T. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01864-6 · Cited by 1
Kandalam, S., Benamar, M., Reun, C. L., Rengger, L., Gupta, P., & Nair, S. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01847-7 · Cited by 1
“…with IDegLira, which is in line with evidence from recent NMAs [2, 35] and semaglutide cardiovascular outcome trials (SUSTAIN 6, SOUL, and FLOW [36–38]), and supports GLP-1 RAs as effective therapy for patients requiring basal insulin intensification, with demonstrated cardiovascular and renal…”
Embracing the Generational Opportunity to Improve the Care of Kidney Disease
Chertow, G. M. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.01.023 · Cited by 1
2024 Taiwan clinical practice guideline for diabetic kidney disease – an executive summary
Su, S., Chang, T.-C., Chiu, Y., Chu, C., Hsu, Y., Kuo, C., Lee, C., Lin, M., Lin, C., Lin, Y.-F., et al. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.08.020 · Cited by 3
Challenges and opportunities in managing individuals with obesity on peritoneal dialysis
Abra, G. E. (2025) · Peritoneal Dialysis International · doi:10.1177/08968608251360297 · Cited by 1
Wang, J., Fan, Y., Dube, S., Benz, P. M., Dube, D. K., Sanger, J. M., & Sanger, J. W. (2024) · Cytoskeleton · doi:10.1002/cm.21950 · Cited by 1
Asymptomatic Subcutaneous Semaglutide Overdose: A Case Report and Literature Review
Diec, C. B., Cook, E. A., & Nguyen, N. T. (2025) · Journal of Pharmacy Practice · doi:10.1177/08971900251335111 · Cited by 2
Ortiz-Seller, A., Real, J. T., Morcillo, E. J., & Ortiz, J. L. (2026) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2026.08.007 · Cited by 1
Diabetes in kidney disease progression
Caberto, S. C., Schlanger, L. E., & Fadem, S. Z. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34069-7.00018-5
Riccardi, M., Ostrominski, J. W., Chatur, S., Lombardi, C., Volterrani, M., Metra, M., Savarese, G., Vaduganathan, M., Solomon, S. D., & Inciardi, R. M. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag074 · Cited by 1
Pharmacologic Therapy for Type 1 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch01
The Incretin Revolution: Integrating Incretin-Based Therapies into Clinical Care
Wojeck, B. S., & Nokes, B. T. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101038
López, J. P., Capote, P. A. C., Pozo, A. H., Guerra, L. C., García, J. L., Olmo, R. F., & Huete, M. J. E. (2025) · Nefrología · doi:10.1016/j.nefro.2025.501359 · Cited by 1
Managing Heart Failure in Chronic Kidney Disease: A Review of Current Literature
Lidgard, B., & Bansal, N. (2024) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-024-01048-0 · Cited by 1
“The trial was halted early due to efficacy after a median follow-up of 3.4 years; semaglu-tide reduced the risk of progression of CKD and death due to a cardiovascular cause [49].”
InfluentialAktueller Stand der Nephroprotektion in der Diabetologie
Schmieder, R. E., & Striepe, K. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01235-4
Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes
Kishimori, T., Kato, T., Iwasaki, Y., Shimada, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Matsumoto, T., Yagi, T., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70433 · Cited by 1
“24 Regarding the treatment of obesity, the semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) trial showed that once-weekly injectable semaglutide (2.4 mg) in individuals with overweight or obesity without diabetes but with established cardiovascular…”
InfluentialSchmidt, B. M. W. (2025) · Die Nephrologie · doi:10.1007/s11560-025-00835-5
Hansrivijit, P., Patorno, E., Tesfaye, H., Wexler, D. J., & Paik, J. M. (2026) · Kidney360 · doi:10.34067/kid.0000001144
Agarwal, S., Basit, M. A., MARBLE, K., Mai, C., Bowen, M. E., Pak, J., Elnakieb, Y. A., & Lingvay, I. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.07.015
GLP-1 receptor agonists in type 1 diabetes: a new frontier for cardiovascular prevention?
Chen, Q., Abuduhelili, B., Xiao, Y., Chen, Y., Xu, J., & Chen, C. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag371
New and Emerging Nonimmunosuppressive Drug Therapies for Primary Adult Glomerular Diseases
Mushailov, V., & Radhakrishnan, J. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.101133 · Cited by 2
“57-61 It is important to consider that some patients with primary GD, particularly those with FSGS and metabolic comorbid conditions, may already be receiving GLP-1 RA therapy for weight or glycemic control.”
Rangaswami, J., Januzzi, J. L., & Mathew, R. O. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.03.031
Hu, H., Hou, S., Chen, W., & Hu, J. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118405
Hsu, J.-T., Tseng, P.-C., Li, L., Chiou, T. T., Chiu, C.-H., Kuo, P.-Y., Huang, C.-C., Tsai, K., Hsu, T.-W., Wu, P.-J., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19101539
Angioedema After Accidental Semaglutide Dosing Error: A Case Report
Kraft, B. D., & Matuszak, S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103705 · Cited by 1
“The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has increased exponentially over recent years as accumulating data support broad benefits outside of glycemic control, including reducing cardiovascular disease [1,2], kidney disease [3,4], and obesity [5].”
Impact of Glucagon‐Like Peptide‐1 Receptor Agonists on Proteinuria in Kidney Transplant Recipients
Shabanowitz, S., Clark, R., Allen, R. B., Chandran, M. M., & Yang, A. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70123
Pandey, R. K., Imran, M., Manal, I., Ahmad, M., Noor, A., & Rohan, A. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70285 · Cited by 1
“The findings for nsMRAs are consistent with FIDELIO-DKD and FIGARO-DKD, while the findings for GLP-1RAs align with emerging evidence from FLOW supporting a role for these agents in cardio-renal protection [10–12].”
Sepsis and infectious outcomes for GLP-1R agonists in CKD plus type 2 diabetes
Tseng, Y.-Y., Wang, H., Chen, J., Jiang, M., Lai, C., & Chuang, M. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag175
Mutchmore, A., Labossière, M. N., Cauchon, M., Plourde, M.-É., & Lanthier, L. (2025) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2025.05.010
Raveendra, K., Joseph, T., Kang, J., Hurdus, B., Cutting, U., Haris, M., Younsi, T., Aslam, A., Petrie, M. C., Metra, M., et al. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag091
Mamach, A., Woźniak, A., Sobantka, P., Mokrzecki, S., Król, M., Aleksandrowicz, K., Grodzka, Z., Meszka, M., Bełc, E., & Brzezińska, K. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.6653
Eisa, N., & Barood, O. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.11.018 · Cited by 3
In memoriam: George L. Bakris (1952–2024)
Tsioufis, K. P., Sarafidis, P. A., Kalaitzidis, R., Stergiou, G. S., Thomopoulos, C., Dimitriadis, K. S., Manolis, A. J., Boletis, J., Tatakis, F., Filippatos, G. S., et al. (2024) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2024.11.001
Sztanek, F., Lőrincz, H., Harangi, M., & Nagy, A. C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71277 · Cited by 1
Maqsood, A., Khan, A. R., Aaqil, S. I., Cheema, A. A. A., Ali, M., Jacob, J., Muhammad, N., & Siddiqi, A. K. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000005191 · Cited by 2
“Semaglutide also improved renal outcomes, reducing major kidney disease events in patients with type 2 diabetes and chronic kidney disease by 24% [hazard ratio (HR) 0.76; 95% confidence interval (CI) 0.66–0.88; P = 0.0003] [2] .”
InfluentialChowdhury, D., Dubey, P., Manna, R., Paliwal, S. K., & Bodakhe, S. H. (2026) · Precision medication. · doi:10.1016/j.prmedi.2026.100114
Nguefang, G., Boateng, S., Issaka, Y., Landa, E. L., Gyabaah, S., Mekontso, J. G. K., & Njei, B. M. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08864-2
Ramsbacher, N., & Neumiller, J. J. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408486-references
Bozkurt, B. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102631
Chandra, M. S., Gagliano‐Jucá, T., Shekhar, S., Pencina, K. M., Travison, T. G., Garg, R., McDonnell, M. E., Reid, K. F., Latham, N. K., Lam, H., et al. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106700
“40 UACR will be measured at baseline and during weeks 6, 12, 18, 24, and 36.”
Reule, S. A., Pickthorn, S., Worwa, S., Ishani, A., & Foley, R. N. (2025) · Diabetology · doi:10.3390/diabetology6120161 · Cited by 1
Progressionshemmung bei chronischer Nierenkrankheit
Weinmann-Menke, J., & Galle, J. (2026) · Die Innere Medizin · doi:10.1007/s00108-026-02145-x
Bhaduri, G., BHATTACHARYYA, S., Mukherjee, S., & Gokalani, R. A. (2026) · Acta Diabetologica · doi:10.1007/s00592-025-02636-7
Why wait? Early combination therapy in diabetic kidney disease: lessons from CONFIDENCE
Ponlot, E., & Jadoul, M. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.132
Integrating and Simplifying Evidence to Optimize Cardiorenal Guideline-Directed Therapies
Singh, H., Puckett, C., & Lucas, Y. Q. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165883
“The Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW trial) [71] is the first to specifically investigate the primary kidney-protective effects of a GLP-1RA in patients with eGFR as low as 25 mL/min/1.73 m 2 .”
InfluentialTwenty Years of CKD Surveillance
Reule, S. A., & Ishani, A. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001157
Kristensen, J. B., Nøhr-Meldgaard, J., Pors, S. E., Norlin, J., Veidal, S. S., Bendtsen, K. M., Niss, K., Andersen, M. W., Harder, L. M., Dalhoff, M. T., et al. (2026) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00011.2026 · Cited by 1
Dhali, A., Biswas, J., Khan, F., Dahiya, D. S., & Mandal, S. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16080437
“Studies have shown cardiovascular benefit with semaglutide in obesity without diabetes, symptomatic improvement in obesity-related HFpEF, and kidney benefit in type 2 diabetes with chronic kidney disease [14–16].”
Recent advances in the pharmacological treatment of obesity
Nam, G. E. (2025) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0058 · Cited by 1
A New Era in the Management of Patients with Diabetic Kidney Disease using Four Pillars of Therapy
Kourtidou, C., Georgianos, P. I., Liakopoulos, V., Savvopoulos, C., & Τζιόμαλος, Κ. (2026) · Journal of Atherosclerosis Prevention and Treatment · doi:10.4103/aptj.aptj_27_26
Chen, J., Liu, K.-W., Huang, Y., Meyerowitz‐Katz, G., Tsai, T., & Su, P. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261460592 · Cited by 1
“31,32 Renal laboratory changes over 24 months were modest and largely parallel, which does not conflict with the FLOW trial: semaglutide slowed eGFR decline in patients with T2D and established CKD. 16 The difference likely reflects population risk (CKD enrichment in FLOW versus routine-care heterogeneity here) and th…”
Pharmacological Interventions for Diabetes Management
Hay-Bradford, E. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-88835-9_4
Ayalon‐Dangur, I., Jaffe, E., Grossman, A., Hendel, H., Oved, Y., Shaked, A., Shimon, I., Basharim, B., Molhem, M. A., McNeil, R., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14072170
“They have also been shown to have beneficial effects in patients with chronic kidney disease (CKD) [6–8].”
Wolf, G., & Mertens, P. R. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21183-6.00006-4
Kasaie, P., Zhao, Y., Humes, E., Gerace, L., Reid, K. A., Lesko, C. R., Kurgansky, K. E., Koethe, J. R., Rebeiro, P. F., Bourgi, K., et al. (2025) · medRxiv · doi:10.1101/2025.11.05.25339607
Lejsková M.: Selected cardiovascular, renal and metabolic study results published in 2024
Lejsková, M. (2026) · Klinická biochemie a metabolismus · doi:10.61568/kbm.2026.007
Metadata
- Authors
- Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk A/S, Søborg, Denmark.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-11
- Volume
- 391
- Issue
- 2
- Pages
- 109-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4398781461
- Cited by
- 2,099
- References
- 23
- Citations by year
- 2026: 953 · 2025: 863 · 2024: 281
- FWCI
- 551.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- semaglutide, chronic kidney disease, type 2 diabetes, renal failure, estimated glomerular filtration rate decline, cardiovascular mortality, albuminuria, GLP-1 receptor agonists, renal protection, cardiovascular outcomes, albumin-creatinine ratio, kidney transplantation, dialysis, anemia of chronic kidney disease, diabetic nephropathy, SGLT2 inhibitors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.